[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2400904A1 - Preparations pour administration vaginale et leur utilisation comme agents provoquant l'ovulation ou comme agents anti-mitotiques - Google Patents

Preparations pour administration vaginale et leur utilisation comme agents provoquant l'ovulation ou comme agents anti-mitotiques

Info

Publication number
FR2400904A1
FR2400904A1 FR7824516A FR7824516A FR2400904A1 FR 2400904 A1 FR2400904 A1 FR 2400904A1 FR 7824516 A FR7824516 A FR 7824516A FR 7824516 A FR7824516 A FR 7824516A FR 2400904 A1 FR2400904 A1 FR 2400904A1
Authority
FR
France
Prior art keywords
agents
vaginal administration
preparations
mitotic
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7824516A
Other languages
English (en)
Other versions
FR2400904B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP52101945A external-priority patent/JPS6047249B2/ja
Priority claimed from JP3933778A external-priority patent/JPS54132221A/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2400904A1 publication Critical patent/FR2400904A1/fr
Application granted granted Critical
Publication of FR2400904B1 publication Critical patent/FR2400904B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Préparation pour administration vaginale Cette préparation contient, comme ingrédient pharmaceutiquement actif principal un peptide ayant une activité d'hormone libérant l'hormone luteinisante et dont l'absorption est améliorée en ajoutant un acide carboxylique aliphatique aquasoluble ayant 2 à 6 atomes de carbone. Utilisation de cette préparation, comme médicament oestrogène ou anti-mitotique.
FR7824516A 1977-08-24 1978-08-23 Preparations pour administration vaginale et leur utilisation comme agents provoquant l'ovulation ou comme agents anti-mitotiques Granted FR2400904A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP52101945A JPS6047249B2 (ja) 1977-08-24 1977-08-24 膣投与剤
JP3933778A JPS54132221A (en) 1978-04-03 1978-04-03 Water-based medicine for vaginal administration

Publications (2)

Publication Number Publication Date
FR2400904A1 true FR2400904A1 (fr) 1979-03-23
FR2400904B1 FR2400904B1 (fr) 1982-07-30

Family

ID=26378690

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7824516A Granted FR2400904A1 (fr) 1977-08-24 1978-08-23 Preparations pour administration vaginale et leur utilisation comme agents provoquant l'ovulation ou comme agents anti-mitotiques

Country Status (8)

Country Link
US (1) US4211769A (fr)
AU (1) AU517349B2 (fr)
CA (1) CA1112570A (fr)
CH (1) CH634992A5 (fr)
DE (1) DE2836631A1 (fr)
FR (1) FR2400904A1 (fr)
GB (1) GB2003386B (fr)
IT (1) IT1098199B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
EP0052510A2 (fr) * 1980-11-18 1982-05-26 Syntex (U.S.A.) Inc. Microencapsulation de polypeptides hydrosolubles
EP0067513A2 (fr) * 1981-05-14 1982-12-22 Takeda Chemical Industries, Ltd. Préparations pharmaceutiques contenant du TRH ou son analogue
EP0130409A2 (fr) * 1983-06-07 1985-01-09 Takeda Chemical Industries, Ltd. Corps composite à libération lente et procédé de sa préparation

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389613A (en) * 1979-09-21 1995-02-14 Roussel Uclaf Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis
EP0041286B1 (fr) * 1980-06-02 1984-08-15 Andrew Victor Schally Antagonistes de la LH-RH
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
GB8308330D0 (en) * 1983-03-25 1983-05-05 Crighton D B Immunogenic compositions
US4801475A (en) * 1984-08-23 1989-01-31 Gregory Halpern Method of hydrophilic coating of plastics
HU193607B (en) * 1985-07-18 1987-11-30 Innofinance Altalanos Innovaci Process for production of sexual products applyable for natural or artificial insemination for mammates
US4663233A (en) * 1985-10-24 1987-05-05 Universal High Technologies Lens with hydrophilic coating
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
EP0259485A4 (fr) * 1986-03-14 1988-07-29 Bio Technology General Corp Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens.
US4784991A (en) * 1986-03-14 1988-11-15 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
JPH01501937A (ja) * 1986-11-18 1989-07-06 セネテック・ピーエルシー 腟潤滑誘発方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3928677C2 (de) * 1989-08-30 1998-05-14 Kimberly Clark Gmbh Tampon für medizinische oder hygienische Zwecke sowie Verfahren zu seiner Herstellung
JP2997488B2 (ja) * 1989-12-25 2000-01-11 興研株式会社 腫瘍細胞増殖抑制剤
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
EP0527241B1 (fr) * 1991-07-15 1994-03-16 Artesan Pharma Gesellschaft mit beschränkter Haftung L'utilisation d'acide ascorbique pour la préparation d'un médicament pour utilisation dans la région génitale
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2145418A1 (fr) 1992-09-29 1994-04-14 John S. Patton Administration pulmonaire de fragments actifs de l'hormone parathyroidienne
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
EP2036541A1 (fr) * 1994-03-07 2009-03-18 Nektar Therapeutics Procédés et compositions pour l'administration pulmonaire d'insuline
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
HUP0100221A3 (en) * 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
WO2001000654A2 (fr) * 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification et stabilisation de produits pharmaceutiques a base de peptides et de proteines
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2002241723A1 (en) * 2000-12-21 2002-07-24 Inhale Therapeutic Systems, Inc. Storage stable powder compositions of interleukin-4 receptor
WO2003053411A1 (fr) 2001-12-19 2003-07-03 Nektar Therapeutics Administration pulmonaire d'aminoglycosides
CA2479751C (fr) 2002-03-20 2008-06-03 Trent Poole Appareil d'inhalation
ATE409220T1 (de) * 2002-03-21 2008-10-15 Bifodan As Lactobacillus-stämme
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
KR101139112B1 (ko) * 2002-06-25 2012-04-30 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
AU2003266142A1 (en) * 2002-09-12 2004-04-30 Biosyn, Inc. Mucus formulation for mucosal surfaces and uses thereof
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
CN101027082A (zh) * 2004-01-12 2007-08-29 曼恩坎德公司 降低2型糖尿病患者血清胰岛素原水平的方法
WO2005072803A1 (fr) * 2004-01-16 2005-08-11 Biodel, Inc. Dispositif d'administration sublinguale de medicaments
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2106790B1 (fr) * 2004-03-12 2012-10-24 Biodel, Inc. Compositions d'alimentation de médicament à action rapide
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
EP2314298B1 (fr) 2004-08-23 2015-05-27 MannKind Corporation Microparticules comprenant des sels de diketopiperazine permettant l'administration de médicaments
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
WO2007098500A2 (fr) 2006-02-22 2007-08-30 Mannkind Corporation Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
WO2008124522A2 (fr) * 2007-04-04 2008-10-16 Biodel, Inc. Formulations contenant de l'amyline
WO2009089181A1 (fr) * 2008-01-04 2009-07-16 Blodel, Inc. Préparations d'insuline pour libération d'insuline en fonction de niveaux de glucose dans les tissus
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (fr) 2009-03-11 2017-03-01 MannKind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
DE102010015350A1 (de) 2010-04-16 2011-10-20 Michael Zimmermann Vaginalapplikator
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
JP2017519769A (ja) * 2014-06-16 2017-07-20 ゾエティス・サービシーズ・エルエルシー ＧｎＲＨを含む膣内製剤
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
WO2018234871A2 (fr) * 2017-06-22 2018-12-27 Viramal Limited Compositions pour administration de médicaments et leurs procédés d'utilisation
IL258017B (en) * 2018-03-11 2019-10-31 Aquafit Intimate Ltd Cervical device and its uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3917825A (en) * 1972-10-12 1975-11-04 Takeda Chemical Industries Ltd Preparation for rectal or vaginal administration containing LH-RH or its analogs
GB1454105A (en) * 1972-11-04 1976-10-27 Hoechst Ag Preparation containing luteinizing hormone-releasing factor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3917825A (en) * 1972-10-12 1975-11-04 Takeda Chemical Industries Ltd Preparation for rectal or vaginal administration containing LH-RH or its analogs
GB1454105A (en) * 1972-11-04 1976-10-27 Hoechst Ag Preparation containing luteinizing hormone-releasing factor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
EP0052510A2 (fr) * 1980-11-18 1982-05-26 Syntex (U.S.A.) Inc. Microencapsulation de polypeptides hydrosolubles
EP0052510A3 (en) * 1980-11-18 1982-09-08 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
EP0067513A2 (fr) * 1981-05-14 1982-12-22 Takeda Chemical Industries, Ltd. Préparations pharmaceutiques contenant du TRH ou son analogue
EP0067513A3 (en) * 1981-05-14 1983-10-05 Takeda Chemical Industries, Ltd. Pharmaceutical preparations containing trh or its analogue
EP0130409A2 (fr) * 1983-06-07 1985-01-09 Takeda Chemical Industries, Ltd. Corps composite à libération lente et procédé de sa préparation
EP0130409A3 (fr) * 1983-06-07 1986-07-02 Takeda Chemical Industries, Ltd. Corps composite à libération lente et procédé de sa préparation

Also Published As

Publication number Publication date
AU3918378A (en) 1980-02-28
GB2003386B (en) 1982-06-16
GB2003386A (en) 1979-03-14
IT1098199B (it) 1985-09-07
FR2400904B1 (fr) 1982-07-30
CH634992A5 (de) 1983-03-15
IT7826956A0 (it) 1978-08-23
US4211769A (en) 1980-07-08
AU517349B2 (en) 1981-07-23
CA1112570A (fr) 1981-11-17
DE2836631A1 (de) 1979-03-08

Similar Documents

Publication Publication Date Title
FR2400904A1 (fr) Preparations pour administration vaginale et leur utilisation comme agents provoquant l'ovulation ou comme agents anti-mitotiques
BLATT et al. Vitamin E and climacteric syndrome: failure of effective control as measured by menopausal index
Fabro et al. Toxicity and teratogenicity of optical isomers of thalidomide
Csapo The prospects of PGs in postconceptional therapy
HUP0201145A2 (hu) Prosztaglandin E1 leadására szolgáló helyileg adagolandó készítmények
EP0814800A1 (fr) Creme pour application locale a base d'eau contenant de la nitroglycerine, et son procede de preparation et d'utilisation
ES8100883A1 (es) Procedimiento para la produccion de un preparado farmaceuti-co
KR20050009723A (ko) 신규 에토노게스트렐 에스테르
PT759693E (pt) Processos para a identificacao de compostos capazes de anular as interaccoes de ligacao de vpr-rip-1 de vih-1
FR2448899A1 (fr) Utilisation therapeutique de l'acide 6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxalinecarboxylique et de ses esters
US3882241A (en) Use of prostaglandins E and F for prevention of pregnancy in humans
Huggins et al. Inhibitory effects of ethyl carbamate on prostatic cancer
FR2420974A1 (fr) Medicament a base de derives de l'uracile
Scublinsky et al. THE CONTRACEPTIVE ACTION OF IMPEDING OESTROGENS
Wotiz et al. The contraceptive action of impeding oestrogens
GB1246639A (en) Dehydroepiandrosterone esters
FR2405712A1 (fr) Composes de la serie des pregnanes avec une fonction oxygene en position 19, procede de preparation et preparations pharmaceutiques qui contiennent ces composes
Hall Clinical experiences with the sublingual administration of alpha estradiol
LINSK et al. The effect of phenylbutazone and a related analogue (G25671) upon thyroid function
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
Lemay et al. Efficacy and safety of LHRH agcnist treatment in 10 patients with endometriosis
GB1493237A (en) Pharmaceutical preparations for the treatment of hyperuricacidemia
Simpson et al. The excretion of synthetic oestrogens as ethereal sulphates and monoglucuronides in the rabbit and in man
GOLDFARB et al. The anabolic effects of norethandrolone, a 19-nortestosterone derivative
JUNGCK et al. Estrogenic activity of monobenzyl ether of stilbestrol in the human

Legal Events

Date Code Title Description
ST Notification of lapse